A 630 Million-Person Weight Challenge: Obesity Becomes a Major Public Health Issue in China
According to a report by Malay Mail, about 630 million people in China are overweight or obese — nearly half the population. Obesity is far more than a matter of appearance: it is a major risk factor for hypertension, type 2 diabetes, fatty liver disease, sleep apnea and cardiovascular disease. For years, weight management relied mainly on diet, exercise and lifestyle changes, with limited drug options that were mostly injectable.
What Does the First Oral GLP-1 Weight-Loss Pill Mean?
GLP-1 (glucagon-like peptide-1) receptor agonists were originally developed for diabetes. By mimicking gut hormones, they slow gastric emptying, increase satiety and reduce food intake, helping control both blood sugar and body weight. The approval of the first oral GLP-1 weight-loss drug matters because:
- More patient-friendly: No injections, reducing needle aversion and improving the likelihood of long-term adherence.
- Broader reach: Offers a new option for people who are unwilling or unable to use injectables.
- Earlier chronic-disease intervention: Intervening at the prediabetes or obesity-with-hypertension stage may lower later cardiovascular risk.
Who May Be Suitable for GLP-1 Drugs?
Clinically, GLP-1 weight-loss drugs are generally indicated for adults with a BMI in the obesity range, or those who are overweight with at least one weight-related complication such as hypertension, type 2 diabetes, dyslipidemia or sleep apnea. These are prescription medicines and must be used under medical evaluation — they are not a shortcut to effortless weight loss.
Common Side Effects and Safety Reminders
- Gastrointestinal effects: Nausea, vomiting, diarrhea and constipation are common and usually ease over time.
- Gradual dose escalation: Starting low reduces intolerance risk.
- Caution in special groups: Tell your doctor about a family history of medullary thyroid cancer, pancreatitis or severe gastrointestinal disease.
- Weight regain after stopping: Medication should be combined with diet and exercise, or weight may return after discontinuation.
Weight Loss Is Not the Endpoint — Metabolic Health Is
The goal of obesity management is not just a lower number on the scale, but overall improvement in blood pressure, blood sugar, lipids and sleep quality. People who are overweight should regularly monitor weight, waist circumference, fasting glucose and blood pressure, and keep a long-term health record. Medication is a tool; lifestyle is the foundation — combining both delivers sustainable metabolic benefits.
For daily management, you can use the Xiaoshu Health App to sync with Apple Health and track relevant metrics, keeping weight, blood pressure, blood sugar and sleep data in one place for easier conversations with your doctor and timely adjustments to your weight and chronic-disease plan.